vs
百利高（PRGO）与罗致恒富（RHI）财务数据对比。点击上方公司名可切换其他公司
罗致恒富的季度营收约是百利高的1.2倍（$1.3B vs $1.1B），百利高同比增速更快（-2.5% vs -5.8%），罗致恒富自由现金流更多（$170.8M vs $148.6M），过去两年百利高的营收复合增速更高（1.3% vs -6.1%）
百利高（Perrigo）是一家注册于爱尔兰的非处方仿制药生产商，主打自有品牌OTC药品业务。公司70%的净销售额来自美国医疗市场，为优化税务布局将法定总部设在爱尔兰，该地区销售额仅占总营收的0.6%，2013年曾完成美国历史上第六大企业税收倒置交易。
罗致恒富是1948年成立的国际人力资源咨询机构，总部位于加利福尼亚州门洛帕克和圣拉蒙，是全球规模领先的会计与金融领域人才派遣服务商之一，在全球范围内设有超过345个办公点。
PRGO vs RHI — 直观对比
营收规模更大
RHI
是对方的1.2倍
$1.1B
营收增速更快
PRGO
高出3.3%
-5.8%
自由现金流更多
RHI
多$22.2M
$148.6M
两年增速更快
PRGO
近两年复合增速
-6.1%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $1.3B |
| 净利润 | $-1.4B | — |
| 毛利率 | 32.6% | 37.6% |
| 营业利润率 | -116.0% | 1.7% |
| 净利率 | -127.8% | — |
| 营收同比 | -2.5% | -5.8% |
| 净利润同比 | -3093.9% | — |
| 每股收益（稀释后） | $-10.23 | $0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PRGORHI
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.0B | $1.4B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $1.0B | $1.4B | ||
| Q4 24 | $1.1B | $1.4B | ||
| Q3 24 | $1.1B | $1.5B | ||
| Q2 24 | $1.1B | $1.5B | ||
| Q1 24 | $1.1B | $1.5B |
净利润PRGORHI
| Q4 25 | $-1.4B | — | ||
| Q3 25 | $7.5M | $42.9M | ||
| Q2 25 | $-8.4M | $41.0M | ||
| Q1 25 | $-6.4M | $17.4M | ||
| Q4 24 | $-44.4M | — | ||
| Q3 24 | $-21.0M | $65.5M | ||
| Q2 24 | $-108.4M | $68.2M | ||
| Q1 24 | $2.0M | $63.7M |
毛利率PRGORHI
| Q4 25 | 32.6% | 37.6% | ||
| Q3 25 | 36.1% | 37.2% | ||
| Q2 25 | 34.4% | 37.2% | ||
| Q1 25 | 37.6% | 36.9% | ||
| Q4 24 | 33.9% | 38.8% | ||
| Q3 24 | 37.2% | 39.0% | ||
| Q2 24 | 37.0% | 39.2% | ||
| Q1 24 | 33.1% | 38.1% |
营业利润率PRGORHI
| Q4 25 | -116.0% | 1.7% | ||
| Q3 25 | 7.0% | 1.0% | ||
| Q2 25 | 4.3% | 0.1% | ||
| Q1 25 | 4.5% | 2.9% | ||
| Q4 24 | 10.0% | 4.7% | ||
| Q3 24 | 7.4% | 4.1% | ||
| Q2 24 | -2.5% | 5.1% | ||
| Q1 24 | -5.1% | 2.8% |
净利率PRGORHI
| Q4 25 | -127.8% | — | ||
| Q3 25 | 0.7% | 3.2% | ||
| Q2 25 | -0.8% | 3.0% | ||
| Q1 25 | -0.6% | 1.3% | ||
| Q4 24 | -3.9% | — | ||
| Q3 24 | -1.9% | 4.5% | ||
| Q2 24 | -10.2% | 4.6% | ||
| Q1 24 | 0.2% | 4.3% |
每股收益（稀释后）PRGORHI
| Q4 25 | $-10.23 | $0.32 | ||
| Q3 25 | $0.05 | $0.43 | ||
| Q2 25 | $-0.06 | $0.41 | ||
| Q1 25 | $-0.05 | $0.17 | ||
| Q4 24 | $-0.32 | $0.53 | ||
| Q3 24 | $-0.15 | $0.64 | ||
| Q2 24 | $-0.79 | $0.66 | ||
| Q1 24 | $0.01 | $0.61 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $464.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.9B | $1.3B |
| 总资产 | $8.5B | $2.9B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PRGORHI
| Q4 25 | — | $464.4M | ||
| Q3 25 | $432.1M | $365.3M | ||
| Q2 25 | $454.2M | $380.5M | ||
| Q1 25 | $409.9M | $342.5M | ||
| Q4 24 | $558.8M | $537.6M | ||
| Q3 24 | $1.5B | $570.5M | ||
| Q2 24 | $542.8M | $547.4M | ||
| Q1 24 | $658.5M | $540.9M |
股东权益PRGORHI
| Q4 25 | $2.9B | $1.3B | ||
| Q3 25 | $4.4B | $1.3B | ||
| Q2 25 | $4.5B | $1.3B | ||
| Q1 25 | $4.4B | $1.3B | ||
| Q4 24 | $4.3B | $1.4B | ||
| Q3 24 | $4.6B | $1.5B | ||
| Q2 24 | $4.5B | $1.5B | ||
| Q1 24 | $4.7B | $1.5B |
总资产PRGORHI
| Q4 25 | $8.5B | $2.9B | ||
| Q3 25 | $10.1B | $2.8B | ||
| Q2 25 | $10.1B | $2.8B | ||
| Q1 25 | $9.8B | $2.7B | ||
| Q4 24 | $9.6B | $2.9B | ||
| Q3 24 | $11.2B | $3.0B | ||
| Q2 24 | $10.4B | $2.9B | ||
| Q1 24 | $10.6B | $2.9B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.4M | $182.5M |
| 自由现金流经营现金流 - 资本支出 | $148.6M | $170.8M |
| 自由现金流率自由现金流/营收 | 13.4% | 13.1% |
| 资本支出强度资本支出/营收 | 2.4% | 0.9% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $145.1M | $266.8M |
8季度趋势，按日历期对齐
经营现金流PRGORHI
| Q4 25 | $175.4M | $182.5M | ||
| Q3 25 | $51.7M | $77.4M | ||
| Q2 25 | $75.9M | $119.4M | ||
| Q1 25 | $-64.5M | $-59.3M | ||
| Q4 24 | $312.6M | $154.8M | ||
| Q3 24 | $42.2M | $129.6M | ||
| Q2 24 | $9.5M | $142.0M | ||
| Q1 24 | $-1.4M | $-15.9M |
自由现金流PRGORHI
| Q4 25 | $148.6M | $170.8M | ||
| Q3 25 | $29.8M | $63.6M | ||
| Q2 25 | $56.7M | $104.2M | ||
| Q1 25 | $-90.0M | $-71.7M | ||
| Q4 24 | $274.9M | $140.5M | ||
| Q3 24 | $15.1M | $111.8M | ||
| Q2 24 | $-18.9M | $129.6M | ||
| Q1 24 | $-26.5M | $-27.7M |
自由现金流率PRGORHI
| Q4 25 | 13.4% | 13.1% | ||
| Q3 25 | 2.9% | 4.7% | ||
| Q2 25 | 5.4% | 7.6% | ||
| Q1 25 | -8.6% | -5.3% | ||
| Q4 24 | 24.2% | 10.2% | ||
| Q3 24 | 1.4% | 7.6% | ||
| Q2 24 | -1.8% | 8.8% | ||
| Q1 24 | -2.4% | -1.9% |
资本支出强度PRGORHI
| Q4 25 | 2.4% | 0.9% | ||
| Q3 25 | 2.1% | 1.0% | ||
| Q2 25 | 1.8% | 1.1% | ||
| Q1 25 | 2.4% | 0.9% | ||
| Q4 24 | 3.3% | 1.0% | ||
| Q3 24 | 2.5% | 1.2% | ||
| Q2 24 | 2.7% | 0.8% | ||
| Q1 24 | 2.3% | 0.8% |
现金转化率PRGORHI
| Q4 25 | — | — | ||
| Q3 25 | 6.89× | 1.80× | ||
| Q2 25 | — | 2.91× | ||
| Q1 25 | — | -3.42× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.08× | ||
| Q1 24 | -0.70× | -0.25× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
RHI
| Finance And Accounting | $535.2M | 41% |
| Protiviti | $479.0M | 37% |
| Technology | $156.4M | 12% |
| Permanent Placement Talent Solutions | $102.6M | 8% |
| Other | $29.2M | 2% |
